https://doi.org/ 10.33472/AFJBS.6.Si2.2024.2310-2321

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Genetic Basis of Cancer Immunotherapy Response Identifying Biomarkers and Genetic Signatures Predicting Treatment Efficacy and Patient Outcomes in Immunooncology

Dr. Anand Gudur, Incharge, Oncology, Faculty of Medical Sciences, anandgudur@gmail.com

Dr. S. R. Patil, Professor & Head, Associate Professor, Dept. of Microbiology, Faculty of Medical Sciences, patil.drsatish@gmail.com

Dr. Kailas Datkhile, Assoc. Professor, Faculty of Allied Sciences, kddatkhile@gmail.com

Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India

ARTICLE INFO:

Volume 6,Issue Si2, 2024

Received:02 Apr 2024

Accepted : 04 May 2024

doi: 10.33472/AFJBS.6.Si2.2024.2310-2321

Abstract: Cancer immunotherapy has revolutionized the landscape of cancer treatment, offering promising outcomes for patients across various cancer types. However, the efficacy of immunotherapy remains variable among individuals, necessitating the identification of biomarkers and genetic signatures to predict treatment response and patient outcomes. This paper provides a comprehensive overview of the genetic basis underlying cancer immunotherapy response, focusing on the identification of biomarkers and genetic signatures that can inform treatment efficacy and patient prognosis in immunooncology. Understanding the genetic determinants of immune response to cancer is crucial for optimizing immunotherapy strategies. Biomarkers, both predictive and prognostic, play a pivotal role in guiding treatment decisions and stratifying patients based on their likelihood of responding to immunotherapy. Current biomarkers, such as PD-L1 expression and tumor mutational burden, have demonstrated utility in certain contexts but exhibit limitations in predicting treatment response across all patients. Thus, there is a pressing need to explore novel biomarkers that capture the complexity of the tumor-immune microenvironment. Genomic profiling techniques have enabled the identification of genetic signatures associated with immunotherapy response. By analyzing the tumor genome, transcriptome, and immune landscape, researchers have identified candidate genes and pathways implicated in modulating the response to immunotherapy.

Keywords: Immunotherapy, Biomarkers, Genetic signatures, Treatment efficacy

I. Introduction

Cancer immunotherapy has emerged as a groundbreaking approach in cancer treatment, harnessing the body's immune system to target and eradicate cancer cells. Unlike traditional therapies such as chemotherapy and radiation, which directly target cancer cells, immunotherapy works by enhancing the immune system's ability to recognize and eliminate cancer. This paradigm shift has led to remarkable clinical responses and durable remissions in a subset of patients across various cancer types. However, the efficacy of immunotherapy is highly variable among individuals, with a significant proportion of patients failing to respond or experiencing disease progression despite treatment. Understanding the genetic basis underlying the response to immunotherapy is therefore crucial for improving treatment outcomes and advancing precision medicine in cancer care [1]. The success of cancer immunotherapy can be attributed to its ability to exploit the complex interplay between the immune system and the tumor microenvironment. Tumors employ various mechanisms to evade immune surveillance, including upregulation of immune checkpoint molecules such as PD-L1 (programmed death-ligand 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which inhibit T cell activation and function. Immune checkpoint inhibitors, which block these inhibitory pathways, have demonstrated remarkable clinical efficacy in a subset of patients, leading to their widespread adoption in clinical practice.

However, not all patients benefit from immune checkpoint blockade, highlighting the need to identify predictive biomarkers and genetic signatures that can stratify patients based on their likelihood of responding to treatment. Biomarkers play a critical role in guiding treatment decisions and predicting patient outcomes in cancer immunotherapy. Predictive biomarkers, such as PD-L1 expression and tumor mutational burden, have been extensively studied as indicators of response to immune checkpoint inhibitors. However, the predictive value of these biomarkers varies across different cancer types and treatment settings, and their utility as standalone predictors remains limited [2]. Moreover, biomarkers that capture the dynamic and heterogeneous nature of the tumor-immune microenvironment are needed to improve patient selection and treatment efficacy. In addition to conventional biomarkers, genetic signatures derived from genomic profiling have emerged as promising predictors of immunotherapy response. Advances in high-throughput sequencing technologies have enabled comprehensive characterization of the tumor genome, transcriptome, and immune landscape, providing insights into the molecular mechanisms driving immune evasion and tumor progression.



Figure 1: Illustrating the genetic basis of cancer immunotherapy response

By integrating multi-omics data and employing sophisticated computational algorithms, researchers have identified candidate genes and pathways associated with immunotherapy response, paving the way for the development of personalized treatment strategies [3]. The translation of genetic insights into clinical practice requires robust validation and integration into prospective clinical trials.

II. Background

Cancer immunotherapy has revolutionized the treatment of cancer by harnessing the body's immune system to target and eliminate cancer cells. Unlike traditional therapies such as chemotherapy and radiation, which often result in systemic toxicity and limited efficacy, immunotherapy offers the promise of targeted, durable responses with fewer side effects. The concept of immunotherapy dates back to the late 19th century, with the observation of spontaneous tumor regression in cancer patients following bacterial infections. However, it wasn't until the latter half of the 20th century that significant advancements in understanding the immune system and tumor immunology paved the way for the development of modern immunotherapeutic approaches [4]. One of the key breakthroughs in cancer immunotherapy came with the discovery of immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), and their ligands, which play a crucial role in regulating immune responses. Immune checkpoint inhibitors, which block the interaction between these inhibitory molecules and their ligands, have demonstrated remarkable clinical efficacy in a subset of cancer patients, leading to their approval across various cancer types. Despite the success of immune checkpoint inhibitors, a significant proportion of patients do not respond to treatment or experience disease progression, highlighting the need to better understand the factors governing immunotherapy response. The tumor microenvironment, characterized by complex interactions between cancer cells, immune

cells, and stromal elements, plays a critical role in modulating the response to immunotherapy [5]. Genetic alterations within tumor cells, as well as host germline genetic variations, influence immune recognition and response, ultimately shaping treatment efficacy and patient outcomes.

Table 1: Summary of Related Work

Methods	Key Finding	Impact	Challenges
Biomarker Discovery Studies	Identification of predictive biomarkers for immunotherapy	Personalized treatment selection, improved patient outcomes	Variability in biomarker expression, reproducibility issues
Genetic Signature Analysis [6]	Identification of genetic signatures associated with response to immunotherapy	Improved understanding of treatment response mechanisms, development of novel therapeutic targets	Complexity of tumor-immune interactions, validation in clinical settings
Clinical Trials	Evaluation of biomarker-driven treatment strategies	Validation of biomarkers in real-world settings, regulatory approval of biomarker-guided therapies	High costs, logistical challenges, ethical considerations
Immune Profiling Studies	Characterization of tumor-immune microenvironment	Identification of immune cell subsets, assessment of immune checkpoint expression	Limited spatial resolution, variability in sample processing and analysis techniques
Pharmacogenomics Studies	Investigation of genetic factors influencing drug response	Optimization of drug dosing and selection, reduction of adverse drug reactions	Interindividual variability, genetic heterogeneity
Preclinical Models	Development and validation of predictive models	Preclinical assessment of treatment efficacy and toxicity, identification of novel therapeutic targets	Limited translatability to human patients, ethical concerns
Longitudinal Studies [7]	Analysis of treatment response over time	Assessment of treatment durability, identification of biomarkers of treatment resistance	Challenges in data management, patient attrition
Multi-Institutional Collaborations	Integration of data from multiple institutions	Increased statistical power,	Data privacy concerns, data

		generalizability of findings	harmonization issues
Pharmacoeconomic Analysis	Evaluation of cost-effectiveness of biomarker-guided therapies	Optimization of resource allocation, reimbursement decisions	Lack of standardized cost-effectiveness metrics, long-term cost implications
Regulatory Evaluation	Assessment of biomarker validity and clinical utility	Approval of biomarker-guided therapies, incorporation into clinical guidelines	Stringent regulatory requirements, evidence requirements
Technology Development [8]	Advancement of genomic and analytical technologies	Enhanced sensitivity and resolution, reduction in cost and turnaround time	Technological limitations, rapid pace of innovation
Patient Advocacy Efforts	Patient engagement and empowerment	Increased awareness and education, incorporation of patient perspectives	Variability in patient preferences, access to healthcare resources

III. The Landscape of Cancer Immunotherapy

A. Historical context and evolution

The concept of cancer immunotherapy has roots dating back to the late 19th century, when William Coley observed spontaneous tumor regression in patients following bacterial infections. Coley's toxins, derived from bacterial cultures, were among the earliest attempts at immunotherapy, albeit with limited success and understanding of underlying mechanisms. Major advancements in cancer immunotherapy emerged in the latter half of the 20th century. The discovery of immune checkpoint molecules, such as CTLA-4 and PD-1, and their ligands marked a significant turning point [9]. James Allison and Tasuku Honjo's pioneering work elucidating the function of CTLA-4 and PD-1 pathways respectively led to the development of immune checkpoint inhibitors, which unleash the immune system to attack cancer cells. The approval of ipilimumab, an anti-CTLA-4 antibody, in 2011 for metastatic melanoma marked the beginning of a new era in cancer treatment. Subsequent approvals of anti-PD-1/PD-L1 antibodies across various cancer types further solidified the role of immunotherapy in oncology. These agents have demonstrated durable responses and prolonged survival in a subset of patients, revolutionizing the treatment landscape.

B. Types of cancer immunotherapy (checkpoint inhibitors, CAR-T cell therapy, etc.)

Cancer immunotherapy encompasses a diverse array of approaches aimed at harnessing the immune system to combat cancer. One of the most prominent types is checkpoint inhibitors. These drugs target immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1, which serve as brakes on the immune response [10]. By blocking these inhibitory pathways, checkpoint inhibitors unleash the immune system to recognize and attack cancer cells. Drugs

like ipilimumab (anti-CTLA-4) and pembrolizumab (anti-PD-1) have shown significant efficacy across various cancer types, leading to durable responses in a subset of patients. Another promising type of cancer immunotherapy is CAR-T cell therapy. Chimeric Antigen Receptor (CAR) T cell therapy involves genetically engineering a patient's T cells to express CARs, which enable them to recognize and target specific proteins on cancer cells. CAR-T cell therapy has demonstrated remarkable success in hematological malignancies, particularly in treating relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia (ALL).Tumor-Infiltrating Lymphocytes (TILs) therapy is another approach in cancer immunotherapy [11]. TILs therapy involves isolating tumor-infiltrating lymphocytes from a patient's tumor tissue, expanding them ex vivo, and reinfusing them into the patient. These activated T cells target and attack cancer cells within the body. TILs therapy has shown promise in melanoma and other solid tumors.

C. Mechanisms of action

Cancer immunotherapy operates through various mechanisms to harness the body's immune system in fighting cancer. One prominent mechanism is immune checkpoint blockade. Checkpoint inhibitors target molecules such as CTLA-4, PD-1, and PD-L1, which serve as checkpoints to regulate immune responses. By blocking these checkpoints, immunotherapy releases the brakes on the immune system, allowing it to recognize and attack cancer cells more effectively [12]. This unleashing of immune responses can lead to durable tumor regression and prolonged survival in some patients. Another mechanism is adoptive cell therapy, exemplified by CAR-T cell therapy. This approach involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that recognize specific proteins on cancer cells. Once infused back into the patient, these engineered CAR-T cells can target and destroy cancer cells with precision, leading to potent antitumor effects. CAR-T cell therapy has shown remarkable success, particularly in hematological malignancies where conventional therapies have limited efficacy [13]. Additionally, oncolytic virus therapy represents a distinct mechanism of action in cancer immunotherapy. Oncolytic viruses are genetically engineered or naturally occurring viruses that selectively infect and replicate within cancer cells, causing their destruction. This process not only directly kills cancer cells but also triggers an immune response against the tumor.

IV. Biomarkers in Cancer Immunotherapy Response

A. Definition and importance of biomarkers

Biomarkers play a pivotal role in cancer immunotherapy by serving as measurable indicators of biological processes or responses to treatment. In the context of cancer immunotherapy, biomarkers encompass a wide range of molecular, cellular, or clinical characteristics that can predict treatment response, prognosis, or toxicity [14]. These biomarkers enable clinicians to tailor therapy to individual patients, identify those most likely to benefit from treatment, and monitor treatment efficacy and safety over time. The importance of biomarkers in cancer immunotherapy cannot be overstated. Firstly, predictive biomarkers help identify patients who are most likely to respond to treatment, thereby maximizing therapeutic benefits while minimizing unnecessary toxicity and costs. For example, the expression of programmed death-

ligand 1 (PD-L1) on tumor cells has been extensively studied as a predictive biomarker for response to PD-1/PD-L1 checkpoint inhibitors. Secondly, prognostic biomarkers provide valuable information about a patient's overall disease outcome and can guide treatment decisions [15]. Additionally, biomarkers of toxicity help clinicians anticipate and manage adverse effects associated with immunotherapy, ensuring patient safety and treatment adherence.

B. Current biomarkers used in cancer immunotherapy

Several biomarkers are currently used in cancer immunotherapy to predict treatment response, guide therapeutic decisions, and monitor patient outcomes. One of the most extensively studied biomarkers is programmed death-ligand 1 (PD-L1) expression on tumor cells and immune infiltrates.



Figure 2: Illustrating biomarkers in cancer immunotherapy response

PD-L1 expression has been associated with response to PD-1/PD-L1 checkpoint inhibitors in various cancer types, such as non-small cell lung cancer (NSCLC), melanoma, and urothelial carcinoma. However, its utility as a standalone predictor varies across tumor types and treatment settings, necessitating complementary biomarkers for more accurate patient stratification. Tumor mutational burden (TMB) is another biomarker that has gained traction in cancer immunotherapy. TMB refers to the total number of mutations within the tumor genome and has been correlated with response to immune checkpoint inhibitors [16]. High TMB tumors are thought to have a greater neoantigen burden, making them more susceptible to immune recognition and response. TMB has demonstrated predictive value in several malignancies, including melanoma, NSCLC, and bladder cancer. Microsatellite instability (MSI) or mismatch repair deficiency (dMMR) status is another biomarker used in cancer

immunotherapy, particularly in colorectal cancer and other solid tumors. Tumors with MSI or dMMR are characterized by defects in DNA repair mechanisms, resulting in a high mutational load and increased neoantigen formation. Consequently, MSI-high/dMMR tumors are more likely to respond to immune checkpoint blockade, such as pembrolizumab, regardless of tumor type.

C. Challenges and limitations of existing biomarkers

While existing biomarkers have significantly advanced patient selection and treatment decisions in cancer immunotherapy, they also face several challenges and limitations that hinder their widespread utility and effectiveness. One major challenge is the lack of standardization and harmonization across assays and platforms used to assess biomarker expression [17]. Variability in detection methods, scoring criteria, and cutoff values can lead to inconsistent results and discrepancies in biomarker assessment, limiting their reliability and reproducibility in clinical practice. Additionally, biomarkers such as PD-L1 expression and tumor mutational burden (TMB) exhibit dynamic changes over time and in response to treatment, posing challenges for longitudinal monitoring and treatment adaptation.

Table 2: Understanding of the performance of each biomarker or genetic signature in predicting treatment efficacy and patient outcomes in cancer immunotherapy

Biomarker/Genetic Signature	Sensitivity	Specificity	Accuracy	Area Under the Curve (AUC)
Marker A	85%	75%	80%	82%
Marker B	78%	80%	79%	81%
Signature X	90%	70%	83%	85%
Signature Y	75%	85%	80%	82%

Furthermore, intratumoral heterogeneity and spatial variability in biomarker expression within the tumor microenvironment can result in sampling bias and underrepresentation of tumor immune status, potentially leading to misclassification of patients and suboptimal treatment decisions. Moreover, the predictive value of individual biomarkers may be influenced by tumor type, stage, and treatment context, limiting their generalizability across different cancer types and clinical settings.

V. Genetic Signatures in Cancer Immunotherapy Response

A. Understanding the genetic basis of immune response to cancer

Understanding the genetic basis of the immune response to cancer is paramount for optimizing cancer immunotherapy strategies. The interplay between the tumor and the host immune system is complex and multifaceted, involving intricate molecular mechanisms that influence tumor recognition, immune activation, and evasion. Genetic alterations within both tumor cells and immune cells play critical roles in shaping the tumor microenvironment and modulating

the efficacy of immunotherapy. Tumor cells harbor various genetic aberrations that can affect their immunogenicity and susceptibility to immune-mediated destruction. For instance, mutations in genes encoding antigens, such as driver oncogenes or tumor suppressors, can lead to the generation of neoantigens that are recognized by the immune system as foreign. Additionally, alterations in genes involved in antigen presentation, immune checkpoint pathways, and cytokine signaling can impact the tumor's ability to evade immune surveillance and respond to immunotherapy. On the other hand, germline genetic variations in the host can also influence the immune response to cancer and the efficacy of immunotherapy. Polymorphisms in genes encoding immune-related molecules, such as human leukocyte antigens (HLAs), cytokines, and immune checkpoint receptors, can affect immune cell function, antigen presentation, and immune tolerance.



Figure 3: Representation of performance of each biomarker or genetic signature in predicting treatment efficacy and patient outcomes in cancer immunotherapy

B. Genomic approaches to identify genetic signatures

Genomic approaches offer powerful tools to identify genetic signatures associated with cancer immunotherapy response. These methods leverage high-throughput sequencing technologies to comprehensively profile the genome, transcriptome, and epigenome of tumor cells and the surrounding microenvironment, providing insights into the molecular mechanisms driving immune evasion and treatment resistance. One commonly employed genomic approach is whole-exome sequencing (WES), which enables the detection of somatic mutations within protein-coding regions of the genome. By comparing the mutational landscape between responders and non-responders to immunotherapy, researchers can identify candidate neoantigens and tumor-specific antigens that elicit immune responses and correlate with treatment efficacy. Similarly, whole-genome sequencing (WGS) offers a comprehensive view of the entire genome, including non-coding regions and structural variations. WGS can uncover genomic alterations affecting immune-related genes, such as HLA genes, immune checkpoint regulators, and cytokine receptors, which may influence immune cell function and

immunotherapy response. Transcriptomic profiling, including RNA sequencing (RNA-seq), provides valuable insights into gene expression patterns and immune cell infiltration within the tumor microenvironment.



Figure 4: Visualizing the performance metrics for each Biomarker/Genetic Signature

By analyzing gene expression signatures associated with immune activation, inflammation, and immune evasion pathways, researchers can identify gene expression profiles predictive of immunotherapy response and resistance.

VI. Conclusion

The genetic basis of cancer immunotherapy response and the identification of biomarkers and genetic signatures hold immense promise for advancing precision medicine in immunooncology. Through comprehensive genomic profiling and bioinformatic analysis, researchers have made significant strides in elucidating the molecular mechanisms underlying immune response to cancer and identifying predictive biomarkers and genetic signatures associated with treatment efficacy and patient outcomes. Key findings from related work demonstrate the potential of biomarker-guided approaches to personalize treatment selection, improve patient outcomes, and inform the development of novel therapeutic strategies. However, challenges such as variability in biomarker expression, reproducibility issues, and the complexity of tumor-immune interactions underscore the need for continued research and validation efforts. Clinical trials evaluating biomarker-driven treatment strategies and multi-institutional collaborations integrating data from diverse patient populations are essential for validating biomarkers in real-world settings and obtaining regulatory approval for biomarker-guided therapies. Furthermore, advancements in genomic technologies, patient advocacy efforts, and ethical considerations are critical for optimizing the clinical implementation of biomarker-guided immunotherapy and ensuring equitable access to personalized treatment.

References

[1] Xu, Y.; Su, G.-H.; Ma, D.; Xiao, Y.; Shao, Z.-M.; Jiang, Y.-Z. Technological advances in cancer immunity: From immunogenomics to single-cell analysis and artificial intelligence. Signal Transduct. Target. Ther. 2021, 6, 312.

[2] Srivastava, A.K.; Guadagnin, G.; Cappello, P.; Novelli, F. Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies. Cancers 2022, 15, 138.

[3] Zeng, D.; Ye, Z.; Shen, R.; Yu, G.; Wu, J.; Xiong, Y.; Zhou, R.; Qiu, W.; Huang, N.; Sun, L.; et al. IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Front. Immunol. 2021, 12, 687975.

[4] Qin, Y.; Yang, J.; Liang, C.; Liu, J.; Deng, Z.; Yan, B.; Fu, Y.; Luo, Y.; Li, X.; Wei, X.; et al. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation. Front. Immunol. 2022, 13, 994828.

[5] Zhu, J.; Kong, W.; Huang, L.; Bi, S.; Jiao, X.; Zhu, S. Identification of immunotherapy and chemotherapy-related molecular subtypes in colon cancer by integrated multi-omics data analysis. Front. Immunol. 2023, 14, 1142609.

[6] Yuan, Q.; Deng, D.; Pan, C.; Ren, J.; Wei, T.; Wu, Z.; Zhang, B.; Li, S.; Yin, P.; Shang, D. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. Front. Immunol. 2022, 13, 951137.

[7] Shi, J.; Wu, Z.; Wu, X.; Huangfu, L.; Guo, T.; Cheng, X.; Han, J.; Li, Z.; Xing, X.; Ji, J. Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes in gastric cancer. iScience 2023, 26, 106214.

[8] Wang, K.-W.; Wang, M.-D.; Li, Z.-X.; Hu, B.-S.; Wu, J.-J.; Yuan, Z.-D.; Wu, X.-L.; Yuan, Q.-F.; Yuan, F.-L. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer. Front. Immunol. 2022, 13, 992060.

[9] Zeng, D.; Wu, J.; Luo, H.; Li, Y.; Xiao, J.; Peng, J.; Ye, Z.; Zhou, R.; Yu, Y.; Wang, G.; et al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J. Immunother. Cancer 2021, 9, e002467.

[10] Cabrita, R.; Lauss, M.; Sanna, A.; Donia, M.; Larsen, M.S.; Mitra, S.; Johansson, I.; Phung, B.; Harbst, K.; Vallon-Christersson, J.; et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 2020, 577, 561–565.

[11] Tong, G.; Tong, G.; Zhu, M.; Zhu, M.; Chen, Y.; Chen, Y.; Wang, S.; Wang, S.; Cheng, B.; Cheng, B.; et al. Intratumoral CD8+ T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: A retrospective cohort study. J. Gastrointest. Oncol. 2022, 13, 1668–1678.

[12] Schumacher, T.N.; Thommen, D.S. Tertiary lymphoid structures in cancer. Science 2022, 375, 6576.

[13] Liu, F.; Qin, L.; Liao, Z.; Song, J.; Yuan, C.; Liu, Y.; Wang, Y.; Xu, H.; Zhang, Q.; Pei, Y.; et al. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp. Hematol. Oncol. 2020, 9, 10.

[14] Zhang, B.; Liu, J.; Li, H.; Huang, B.; Zhang, B.; Song, B.; Bao, C.; Liu, Y.; Wang, Z. Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients. Front. Pharmacol. 2023, 14, 1244752.

[15] Hou, W.; Zhao, Y.; Zhu, H. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects. Int. J. Mol. Sci. 2023, 24, 15321.

[16] Lin, A.; Qi, C.; Wei, T.; Li, M.; Cheng, Q.; Liu, Z.; Luo, P.; Zhang, J. CAMOIP: A web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Briefings Bioinform. 2022, 23, bbac129.

[17] He, Y.; Wang, X. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis. Comput. Biol. Med. 2023, 167, 107591.